CN110709091A - 使用长效格拉替雷和脂肪源性干细胞治疗多发性硬化症 - Google Patents

使用长效格拉替雷和脂肪源性干细胞治疗多发性硬化症 Download PDF

Info

Publication number
CN110709091A
CN110709091A CN201780091620.2A CN201780091620A CN110709091A CN 110709091 A CN110709091 A CN 110709091A CN 201780091620 A CN201780091620 A CN 201780091620A CN 110709091 A CN110709091 A CN 110709091A
Authority
CN
China
Prior art keywords
glatiramer acetate
hadscs
pharmaceutical composition
administration
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780091620.2A
Other languages
English (en)
Chinese (zh)
Inventor
埃胡德·马罗姆
纳达夫·布莱希·基梅尔曼
弗里达·格里恩斯潘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stem Cell Medicine Ltd
Mapi Pharma Ltd
Original Assignee
Stem Cell Medicine Ltd
Mapi Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stem Cell Medicine Ltd, Mapi Pharma Ltd filed Critical Stem Cell Medicine Ltd
Publication of CN110709091A publication Critical patent/CN110709091A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Epoxy Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201780091620.2A 2017-05-15 2017-05-15 使用长效格拉替雷和脂肪源性干细胞治疗多发性硬化症 Pending CN110709091A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IL2017/050535 WO2018211486A1 (en) 2017-05-15 2017-05-15 Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells

Publications (1)

Publication Number Publication Date
CN110709091A true CN110709091A (zh) 2020-01-17

Family

ID=64273438

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780091620.2A Pending CN110709091A (zh) 2017-05-15 2017-05-15 使用长效格拉替雷和脂肪源性干细胞治疗多发性硬化症

Country Status (8)

Country Link
US (1) US11413311B2 (enExample)
EP (1) EP3624815A4 (enExample)
JP (1) JP7000458B2 (enExample)
CN (1) CN110709091A (enExample)
AU (1) AU2017414803B2 (enExample)
CA (1) CA3062964C (enExample)
IL (1) IL270355B2 (enExample)
WO (1) WO2018211486A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
HRP20250396T1 (hr) 2016-08-31 2025-05-23 Mapi Pharma Ltd. Depo sustavi koji sadrže glatiramer acetat
AU2018242998B2 (en) * 2017-03-26 2023-11-02 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148419A1 (en) * 2005-12-07 2009-06-11 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
US20090191173A1 (en) * 2004-11-29 2009-07-30 Michal Eisenbach-Schwartz Induction Of Neurogenesis And Stem Cell Therapy In Combination With Copolymer 1
US20120164229A1 (en) * 2010-01-04 2012-06-28 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
CN102686235A (zh) * 2010-01-04 2012-09-19 Mapi医药公司 包含格拉默或其药用盐的储药系统
CN103403150A (zh) * 2010-12-17 2013-11-20 人类起源公司 利用羊膜来源贴壁细胞治疗与免疫相关的疾病和紊乱
CN104203901A (zh) * 2009-04-13 2014-12-10 C.T.瑞瑟露公司 治疗炎症的组合物和方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
DK1248643T3 (da) 2000-01-20 2005-11-07 Yeda Res & Dev Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celler behandlet dermed til neurobeskyttende terapi
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
NZ569331A (en) 2003-01-21 2010-08-27 Yeda Res & Dev COP 1 for treatment of inflammatory bowel diseases
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
WO2006060779A2 (en) 2004-12-03 2006-06-08 Case Western Reserve University Novel methods, compositions and devices for inducing neovascularization
US20070003528A1 (en) 2005-06-29 2007-01-04 Paul Consigny Intracoronary device and method of use thereof
NZ597304A (en) 2005-10-13 2013-06-28 Anthrogenesis Corp Immunomodulation using placental stem cells
WO2008024996A2 (en) 2006-08-24 2008-02-28 Johnstone Brian H Production of neural protective and regenerative factors from stem cells and treatment of nervous system conditions therewith
CA2668200C (en) 2006-11-03 2017-04-18 Multiple Sclerosis Research Center Of New York Bone marrow-derived mesenchymal stem cells as a source of neural progenitors
WO2011041240A1 (en) 2009-09-30 2011-04-07 The Brigham And Women's Hospital, Inc. Tissue transplant compositions and methods for use
US8703180B1 (en) 2007-10-23 2014-04-22 Abbott Cardiovascular Systems Inc. Multiple growth factor compositions, methods of fabrication, and methods of treatment
EP2278873B1 (en) 2008-03-19 2015-05-06 Cryo-Save AG Improved cryopreservation of adipose tissue for the isolation of mesenchymal stem cells
US20090291061A1 (en) 2008-05-21 2009-11-26 Riordan Neil H Stem cell therapy for blood vessel degeneration
DK2285951T3 (en) 2008-05-28 2018-10-22 Univ Ramot TREATMENT OF CNS DISEASES OF CNS DISEASES
WO2010014990A2 (en) 2008-08-01 2010-02-04 The Board Of Trustees Of The University Of Illinois Method of promoting neurogenesis by modulating secretase activities
WO2010028051A2 (en) 2008-09-03 2010-03-11 Florida State University Research Foundation, Inc. Substituted heterocyclic mercaptosulfonamide metalloprotease inhibitors
WO2010045645A1 (en) 2008-10-17 2010-04-22 Baxter International Inc. Methods of obtaining cell populations from adipose tissue
JP5515319B2 (ja) 2009-02-23 2014-06-11 富士レビオ株式会社 脂肪細胞への分化誘導培地及び方法
KR101788885B1 (ko) 2009-07-09 2017-10-20 타이제닉스, 에스.에이.유. 세포 요법에 사용하기 위한 방법 및 조성물
US20110212158A1 (en) 2010-02-18 2011-09-01 Samson Tom Immunocompatible chorionic membrane products
WO2012143924A1 (en) 2011-04-21 2012-10-26 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
US20130034524A1 (en) 2011-08-03 2013-02-07 Siamak Agha-Mohammadi Non-Enzymatic Method for Harvesting Adipose-Derived Stromal Cells and Adipose-Derived Stem Cells from Fat and Lipo-Aspirate
SG10201606745XA (en) 2011-09-23 2016-10-28 Cell Ideas Pty Ltd Therapeutics using adipose cells and cell secretions
CL2011002642A1 (es) 2011-10-24 2012-04-09 Univ Del Desarrollo Uso de una composicion formada por un glucocorticoide y una tiazolinediona que sirve para inducir la diferenciacion adipogenica en celulas madres.
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
SG10201607521PA (en) 2012-03-12 2016-10-28 Univ Singapore Generation of brown adipose tissue (bat) from mesenchymal cells
TWI642781B (zh) 2014-02-06 2018-12-01 仲恩生醫科技股份有限公司 具優異細胞保護及免疫調節之ｑｕａｄｒｉ－正之基質細胞
WO2015120388A1 (en) 2014-02-10 2015-08-13 Cytori Therapeutics, Inc. Regenerative cell therapy for central nervous system (cns) disorders and ptsd
AU2017218143B2 (en) 2016-02-12 2023-08-03 Cell Care Therapeutics, Inc. Adipose tissue derived mesenchymal stromal cell conditioned media and methods of making and using the same
US12161688B2 (en) * 2016-06-30 2024-12-10 Mapi Pharma Ltd Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
CA3062123A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090191173A1 (en) * 2004-11-29 2009-07-30 Michal Eisenbach-Schwartz Induction Of Neurogenesis And Stem Cell Therapy In Combination With Copolymer 1
US20090148419A1 (en) * 2005-12-07 2009-06-11 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
CN104203901A (zh) * 2009-04-13 2014-12-10 C.T.瑞瑟露公司 治疗炎症的组合物和方法
US20120164229A1 (en) * 2010-01-04 2012-06-28 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
CN102686235A (zh) * 2010-01-04 2012-09-19 Mapi医药公司 包含格拉默或其药用盐的储药系统
CN103403150A (zh) * 2010-12-17 2013-11-20 人类起源公司 利用羊膜来源贴壁细胞治疗与免疫相关的疾病和紊乱

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRITTNI A SCRUGGS等: "Age of the donor reduces the ability of human adipose-derived stem cells to alleviate symptoms in the experimental autoimmune encephalomyelitis mouse model", vol. 2, no. 2, pages 798 *
NAZEM GHASEMI等: "Transplantation of human adipose-derived stem cells enhances remyelination in lysolecithin-induced focal demyelination of rat spinal cord", vol. 56, no. 5 *

Also Published As

Publication number Publication date
JP7000458B2 (ja) 2022-02-10
EP3624815A1 (en) 2020-03-25
US20200147141A1 (en) 2020-05-14
US11413311B2 (en) 2022-08-16
IL270355A (enExample) 2019-12-31
IL270355B2 (en) 2023-06-01
CA3062964C (en) 2024-11-12
AU2017414803A1 (en) 2019-12-05
IL270355B1 (enExample) 2023-02-01
JP2020519658A (ja) 2020-07-02
WO2018211486A1 (en) 2018-11-22
CA3062964A1 (en) 2018-11-22
AU2017414803B2 (en) 2025-02-13
EP3624815A4 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
US12161688B2 (en) Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
JP2024129012A (ja) 炎症の治療のための免疫修飾粒子
JP5916622B2 (ja) グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム
JP6837486B2 (ja) 加齢に関連する認知障害及び神経炎症を予防及び／又は治療する方法
US8377885B2 (en) Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
EP3065765B1 (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
EP3506921B1 (en) Depot systems comprising glatiramer acetate
CA3050086A1 (en) Glatiramer depot systems for treating progressive forms of multiple sclerosis
IL270355B2 (en) Treatment of multiple sclerosis using long-acting glatiramer and stem cells derived from adipose tissue
JP7232752B2 (ja) 酢酸グラチラマーを含有する微小粒子を調製する方法
JP6573293B2 (ja) 炎症性疾患の予防または治療用ペプチド及びこの用途
USRE50301E1 (en) Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
KR20040079393A (ko) (-)-에피갈로카테킨 갈레이트를 유효성분으로 하는류마티스성 관절염 치료제
US20230399404A1 (en) Sustained antibody and immunotherapeutic delivery to cervical lymph nodes
US20160022772A1 (en) Cytokine Receptors as Targets for Hypertension Therapy and Methods of Use
HK40005874A (en) Depot systems comprising glatiramer acetate
HK1173383A (en) Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20200117

RJ01 Rejection of invention patent application after publication